Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With Diarrhoea-predominant Irritable Bowel syndrome-a Multicentre Controlled Study
Sponsor: First Affiliated Hospital of Wenzhou Medical University
A PHASE4 clinical study on Gut Microbiota and IBS - Irritable Bowel Syndrome, this trial is ongoing. The trial is conducted by First Affiliated Hospital of Wenzhou Medical University and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Recruiting PHASE4
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Apr 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE4
-
Sep 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital of Wenzhou Medical University
- Peking Union Medical College Hospital
- RenJi Hospital
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Sir Run Run Shaw Hospital
- The Central Hospital of Lishui City
- The First Affiliated Hospital of Zhejiang Chinese Medical University
For direct contact, visit the study record on ClinicalTrials.gov .